Gilead's expansion beyond HIV therapies will surprise many investors.

July 14 () - Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a ...

In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of ...

The Ebola outbreak in eastern Congo is now the fastest-growing one in history and new challenges keep emerging. A strike this ...

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but ...

Bill Lawrence, W. Kamau Bell, Karamo Brown and Baron Davis also join the lineup for the July 22 event, where Gilead Sciences ...

Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead. Learn why ASMB stock is a buy.

Making a creative pharma campaign that earns recognition at the prestigious Cannes Lions Festival of Creativity is a beast. Gilead Sciences conquered the task with the help of some AI-generated ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Gilead Sciences’ Up To Date campaign with comedians Nicole Byer and Devon Walker hopes to normalize conversations about HIV prevention, testing and PrEP. The campaign targets Black women through ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences ...